- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03460977
PF-06821497 Tratamiento de SCLC en recaída/refractario, cáncer de próstata resistente a la castración y linfoma folicular
UNA FASE I ESCALADA DE DOSIS Y ESTUDIO DE COHORTE AMPLIADO DE PF-06821497 EN EL TRATAMIENTO DE PACIENTES ADULTOS CON CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS (CPCP) RECAÍDA O REFRACTARIO, CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN (CPRC) Y LINFOMA FOLICULAR (FL)
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.
Part 3, which is open for enrollment is seeking men who:
- have Castration Resistant Prostate Cancer (CRPC) and
- have previously received treatment for CRPC and have progressed from the last treatment
All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).
In the assessment phase:
- participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
- participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
- participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.
After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.
The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).
Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Pfizer CT.gov Call Center
- Número de teléfono: 1-800-718-1021
- Correo electrónico: ClinicalTrials.gov_Inquiries@pfizer.com
Ubicaciones de estudio
-
-
-
Haskovo, Bulgaria, 6300
- Terminado
- Specialized Hospital for Active Treatment of Oncology - Haskovo
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Corea del Sur, 13620
- Reclutamiento
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [seoul]
-
Seoul, Seoul-teukbyeolsi [seoul], Corea del Sur, 03080
- Activo, no reclutando
- Seoul National University Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Corea del Sur, 07985
- Activo, no reclutando
- Ewha Womans University Mokdong Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Corea del Sur, 03722
- Activo, no reclutando
- Severance Hospital, Yonsei University Health System
-
-
Taejǒn-kwangyǒkshi
-
Daejeon, Taejǒn-kwangyǒkshi, Corea del Sur, 35015
- Activo, no reclutando
- Chungnam national university hospital
-
-
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Hospital Universitari Vall d'Hebron
-
Barcelona, España, 08036
- Reclutamiento
- Hospital Clinic de Barcelona
-
Barcelona, España, 08023
- Reclutamiento
- Hospital Quironsalud Barcelona
-
Madrid, España, 28034
- Reclutamiento
- Hospital Universitario Ramon y Cajal
-
Madrid, España, 28050
- Reclutamiento
- Hospital Universitario HM Sanchinarro
-
Madrid, España, 28040
- Reclutamiento
- H.U. Fundación Jiménez Díaz
-
Madrid, España, 28041
- Reclutamiento
- Hospital Universitario 12 De Octubre
-
Málaga, España, 29010
- Reclutamiento
- Hospital Universitario Virgen de la Victoria
-
Valencia, España, 46026
- Activo, no reclutando
- Hospital Universitari i Politecnic La Fe
-
-
Barecelona
-
L'Hospitalet de Llobregat, Barecelona, España, 08908
- Activo, no reclutando
- Institut Català d´Oncología (ICO)-H. Durán i Reynals
-
-
Castellon
-
Castellon, Castellon, España, 12002
- Activo, no reclutando
- Consorcio Hospitalario Provincial de Castellon
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, España, 28223
- Reclutamiento
- Hospital Quironsalud Madrid
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, España, 28040
- Reclutamiento
- Hospital Clinico San Carlos
-
-
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85719
- Activo, no reclutando
- Banner-University Medical Center Tucson
-
Tucson, Arizona, Estados Unidos, 85719
- Activo, no reclutando
- The University of Arizona Cancer Center-North Campus
-
Tucson, Arizona, Estados Unidos, 85724
- Activo, no reclutando
- The University of Arizona Cancer Center
-
Tucson, Arizona, Estados Unidos, 85741
- Terminado
- Arizona Urology Specialists, PLLC
-
-
California
-
Anaheim, California, Estados Unidos, 92801
- Activo, no reclutando
- Pacific Cancer Medical Center INC
-
Duarte, California, Estados Unidos, 91010
- Activo, no reclutando
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Duarte, California, Estados Unidos, 91010
- Activo, no reclutando
- City of Hope Investigational Drug Services (IDS)
-
-
Connecticut
-
Norwalk, Connecticut, Estados Unidos, 06856
- Activo, no reclutando
- Norwalk Hospital
-
-
Kansas
-
Fairway, Kansas, Estados Unidos, 66205
- Activo, no reclutando
- The University of Kansas Cancer Center, Investigational Drug Services
-
Fairway, Kansas, Estados Unidos, 66205
- Activo, no reclutando
- The University of Kansas Clinical Research Center
-
Kansas City, Kansas, Estados Unidos, 66160
- Activo, no reclutando
- The University of Kansas Hospital
-
Kansas City, Kansas, Estados Unidos, 66160
- Activo, no reclutando
- The University of Kansas Medical Center Medical Office Building
-
Overland Park, Kansas, Estados Unidos, 66211
- Activo, no reclutando
- The University of Kansas Cancer Center - Indian Creek Campus
-
Westwood, Kansas, Estados Unidos, 66205
- Activo, no reclutando
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Activo, no reclutando
- Norton Cancer Institute, Norton Healthcare Pavilion
-
Louisville, Kentucky, Estados Unidos, 40202
- Activo, no reclutando
- Norton Hospital
-
Louisville, Kentucky, Estados Unidos, 40202
- Activo, no reclutando
- Norton Cancer Institute - Downtown
-
-
Maryland
-
Rockville, Maryland, Estados Unidos, 20850
- Terminado
- Maryland Oncology Hematology, P.A.
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Activo, no reclutando
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Estados Unidos, 02115
- Activo, no reclutando
- Brigham and Women's Hospital
-
Newton, Massachusetts, Estados Unidos, 02459
- Activo, no reclutando
- Dana Farber Cancer Institute- Chestnut Hill
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130
- Reclutamiento
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Activo, no reclutando
- Hackensack University Medical Center
-
Hackensack, New Jersey, Estados Unidos, 07601
- Activo, no reclutando
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Reclutamiento
- OU Health University of Oklahoma Medical Center
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Reclutamiento
- Stephenson Cancer Center (chemo location)
-
-
South Carolina
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Reclutamiento
- Carolina Urologic Research Center
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Reclutamiento
- Parkway Surgery Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- Terminado
- Texas Oncology - Austin Midtown
-
Dallas, Texas, Estados Unidos, 75390
- Activo, no reclutando
- UT Southwestern Medical Center
-
Dallas, Texas, Estados Unidos, 75390
- Activo, no reclutando
- University of Texas Southwestern Medical Center - Simmons Cancer Center
-
Dallas, Texas, Estados Unidos, 75390
- Activo, no reclutando
- UT Southwestern University Hospital - William P. Clements, Jr
-
Dallas, Texas, Estados Unidos, 75390
- Activo, no reclutando
- UT Southwestern University Hospital - Zale Lipshy
-
Irving, Texas, Estados Unidos, 75063
- Terminado
- US Oncology Investigational Product Center (IPC)
-
Irving, Texas, Estados Unidos, 75063
- Terminado
- US Oncology Investigational Products Center
-
Irving, Texas, Estados Unidos, 75039
- Reclutamiento
- NEXT Dallas
-
San Antonio, Texas, Estados Unidos, 78229
- Reclutamiento
- NEXT Oncology
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Activo, no reclutando
- Virginia Cancer Specialists, PC
-
-
Washington
-
Port Angeles, Washington, Estados Unidos, 98362
- Activo, no reclutando
- Olympic Medical Center
-
Poulsbo, Washington, Estados Unidos, 98370
- Activo, no reclutando
- Fred Hutchinson Cancer Center Alliance Peninsula
-
Seattle, Washington, Estados Unidos, 98195
- Activo, no reclutando
- University of Washington Medical Center
-
Seattle, Washington, Estados Unidos, 98109
- Activo, no reclutando
- Fred Hutchinson Cancer Center
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japón, 277-8577
- Activo, no reclutando
- National Cancer Center Hospital East
-
-
-
-
-
Bydgoszcz, Polonia, 85-048
- Aún no reclutando
- In-Vivo Sp. z o.o. In-vivo Bydgoszcz
-
Koszalin, Polonia, 75-581
- Activo, no reclutando
- Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
-
Krakow, Polonia, 30-348
- Reclutamiento
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
-
Rzeszów, Polonia, 35-326
- Activo, no reclutando
- Centrum Medyczne MEDYK
-
Warsaw, Polonia, 02-781
- Activo, no reclutando
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510120
- Activo, no reclutando
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha, Hunan, Porcelana, 410013
- Activo, no reclutando
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Porcelana, 210009
- Activo, no reclutando
- Zhongda Hospital Southeast University
-
Nanjing, Jiangsu, Porcelana, 210008
- Activo, no reclutando
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
-
Sichuan
-
Chengdu, Sichuan, Porcelana, 610041
- Reclutamiento
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Wenzhou, Zhejiang, Porcelana, 325000
- Activo, no reclutando
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Moscow, Rusia, 117186
- Activo, no reclutando
- LLC "Neyro-klinika"
-
Moscow, Rusia, 125284
- Terminado
- Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
-
Moscow, Rusia, 129301
- Terminado
- SBHI of Moscow City Clinical Hospital
-
Omsk, Rusia, 644013
- Terminado
- Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
-
Saint Petersburg, Rusia, 197341
- Terminado
- Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
-
Saint Petersburg, Rusia, 197758
- Terminado
- Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
-
Saint Petersburg, Rusia, 198255
- Terminado
- Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
-
Yaroslavl, Rusia, 150054
- Terminado
- State Budgetary Healthcare Institution of the Yaroslavl Region
-
-
Sankt-Peterburg
-
Pushkin, Sankt-Peterburg, Rusia, 196603
- Activo, no reclutando
- Private Medical Institution "Euromedservice"
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Part 1 and Part 2 (Closed for enrollment).
Part 3 Key Inclusion Criteria:
- Histological or cytological diagnosis of castration resistant prostate cancer.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
- Adequate bone marrow, renal, and liver function
Part 3 Key Exclusion Criteria:
- Prior irradiation to >25% of the bone marrow.
- QTcF interval >480 msec at screening.
- Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
- Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
- Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
- Prior enzalutamide within the last 4 weeks
- DDI SUBSTUDY:
- history of CHF or evidence of ventricular dysfunction
- fructose intolerance
- coadministration of CYP3A4 substrates
- Any history of prior malignancies, except for carcinoma in situ or non-melanoma skin cancer, prior non-hematologic malignancies >= 3 years before randomization with no subsequent recurrence or progression, Stage 0 or 1 non-hematologic cancer < 3 years before randomization that has a remote probability of recurrence or progression.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Dose Escalation (Part 1A)
Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels |
Oral continuous
Otros nombres:
|
|
Experimental: Dose Escalation (Part 1B)
Participants with FL will receive mevrometostat at escalating dose levels |
Oral continuous
Otros nombres:
|
|
Experimental: Dose Escalation (Part 1C)
Participants with mCRPC will receive mevrometostat at escalating dose levels. |
Oral continuous
Otros nombres:
|
|
Experimental: Dose Escalation (Part 2A)
Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC. |
Oral continuous
Otros nombres:
Oral continuous
Otros nombres:
|
|
Experimental: Dose Expansion (Part 2B)
Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone. |
Oral continuous
Otros nombres:
Oral continuous
Otros nombres:
|
|
Experimental: Japan Cohort
Participants with CRPC will receive mevrometostat at one or two doses |
Oral continuous
Otros nombres:
|
|
Experimental: China cohort
Participants will receive mevrometostat at one or two doses |
Oral continuous
Otros nombres:
|
|
Experimental: Dose Expansion (Part 2C)
Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC |
Oral continuous
Otros nombres:
Oral continuous
Otros nombres:
|
|
Experimental: BE Substudy
In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Otros nombres:
Oral continuous
Otros nombres:
|
|
Experimental: DDI Substudy
The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Otros nombres:
Oral continuous
Otros nombres:
Oral solution
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Periodo de tiempo: Baseline up to 90 days
|
First cycle DLTs will be utilized to determine the MTD |
Baseline up to 90 days
|
|
Overall safety profile including adverse events
Periodo de tiempo: Baseline up to approximately 2 years
|
Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03]) |
Baseline up to approximately 2 years
|
|
Preliminary efficacy determination as evaluated by disease specific response criteria
Periodo de tiempo: Through study completion, approximately 2 years past last patient first visit.
|
Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC. |
Through study completion, approximately 2 years past last patient first visit.
|
|
Overall safety profile including laboratory abnormalities
Periodo de tiempo: Baseline up to approximately 2 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing. |
Baseline up to approximately 2 years
|
|
Overall safety profile including vital signs
Periodo de tiempo: Baseline up to approximately 2 years
|
Vital sign changes from baseline including blood pressure, heart rate, ECG changes. |
Baseline up to approximately 2 years
|
|
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Periodo de tiempo: Baseline until disease progression or death or through study completion (approx 2 years)
|
PCWG3 |
Baseline until disease progression or death or through study completion (approx 2 years)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Periodo de tiempo: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC) |
Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
|
Evaluate overall survival
Periodo de tiempo: Baseline up to approximately 2 years
|
Median time to death proportion of patients alive at 6 months, 1 year, and 2 years. |
Baseline up to approximately 2 years
|
|
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Periodo de tiempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Periodo de tiempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Periodo de tiempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Periodo de tiempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Periodo de tiempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Periodo de tiempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Singe dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Evaluate the impact of mevrometostat on patient reported outcomes.
Periodo de tiempo: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P. |
At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
|
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Periodo de tiempo: At specific time points from Cycle1 Day 1 to end of treatment
|
Questionnaire customized from PRO-CTCAE. |
At specific time points from Cycle1 Day 1 to end of treatment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Pfizer CT.gov Call Center, Pfizer
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- la seguridad
- farmacocinética
- abierto
- eficacia
- CPRCm
- farmacodinámica
- Florida
- reincidido
- refractario
- cáncer de pulmón de células pequeñas
- escalada de dosis
- SCLC
- linfoma folicular
- expansión de dosis
- EZH2
- cáncer de próstata resistente a la castración
- potenciador de zeste homólogo 2
- estudio-del-cancer-de-prostata.com
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias por sitio
- Neoplasias
- Atributos de la enfermedad
- Enfermedades del sistema inmunológico
- Enfermedades de las vías respiratorias
- Neoplasias por tipo histológico
- Enfermedades pulmonares
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Neoplasias Pulmonares
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Reaparición
- Carcinoma de pulmón de células pequeñas
- Linfoma Folicular
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Azoles
- Triazoles
- Piperazines
- Itraconazol
- enzalutamida
- PF06821497
Otros números de identificación del estudio
- C2321001
- 2023-509179-18-00 (Identificador de registro: CTIS (EU))
- EZH2 (Otro identificador: Alias Study Number)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .